Correspondence: improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study
Pharmacological Research,
Год журнала:
2025,
Номер
213, С. 107639 - 107639
Опубликована: Фев. 1, 2025
Язык: Английский
Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study
Pharmacological Research,
Год журнала:
2025,
Номер
213, С. 107640 - 107640
Опубликована: Фев. 1, 2025
Язык: Английский
Long-term efficacy of daily oral semaglutide as add-on or switch therapy in adults with type 2 diabetes: a 12-month real-world retrospective study
Daniela Sansone,
Francesca Garino,
Cristina Gottero
и другие.
Acta Diabetologica,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 27, 2025
Язык: Английский